Literature DB >> 3279515

Staging and prognosis in chronic myelogenous leukemia.

J E Sokal1, M Baccarani, D Russo, S Tura.   

Abstract

Entities:  

Mesh：

Year:  1988        PMID： 3279515

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  29 in total

1.  Prognostic implications of bone marrow features in chronic myelogenous leukaemia.

Authors:  J Thiele; R Fischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Haematology.

Authors:  N T O'Connor
Journal:  Postgrad Med J       Date:  1990-08       Impact factor: 2.401

3.  Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib.

Authors:  Sandip Ganguly; K C Lakshmaiah; Linu Abraham Jacob; Suresh Babu; Lokanatha Dasappa; K S Govind Babu
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-14       Impact factor: 0.900

Review 4.  Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Timothy P Hughes; Jorge E Cortés; Hagop M Kantarjian; Andreas Hochhaus
Journal:  Leuk Lymphoma       Date:  2013-11-12

5.  Histological features of prognostic significance in CML--an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow.

Authors:  J Thiele; H M Kvasnicka; B R Titius; U Parpert; R Nebel; R Zankovich; D Dienemann; H Stein; V Diehl; R Fischer
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

6.  Extracellular adenosine triphosphate activates calcium mobilization in human phagocytic leukocytes and neutrophil/monocyte progenitor cells.

Authors:  D S Cowen; H M Lazarus; S B Shurin; S E Stoll; G R Dubyak
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

7.  Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.

Authors:  Jorge E Cortes; Michele Baccarani; François Guilhot; Brian J Druker; Susan Branford; Dong-Wook Kim; Fabrizio Pane; Ricardo Pasquini; Stuart L Goldberg; Matt Kalaycio; Beatriz Moiraghi; Jacob M Rowe; Elena Tothova; Carmino De Souza; Marc Rudoltz; Richard Yu; Tillmann Krahnke; Hagop M Kantarjian; Jerald P Radich; Timothy P Hughes
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire.

Authors:  K G Koffi; D C Nanho; E N'dathz; P Kouehion; R Dissieka; A Attia; K Mozard; A Tolo; K Boidy; N Meité; R Ayemou; M Sekongo; N Tea; I Sanogo
Journal:  Adv Hematol       Date:  2010-08-25

Review 9.  Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia.

Authors:  Elias J Jabbour; Jorge E Cortes; Hagop M Kantarjian
Journal:  Expert Rev Anticancer Ther       Date:  2013-12       Impact factor: 4.512

10.  Confirmation and improvement of Sokal's prognostic classification of Ph+ chronic myeloid leukemia: the value of early evaluation of the course of the disease. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.